Photo: Toru Hanai / Reuters
Specialists of the Institute of biomedical research Novartis (USA) conducted clinical trials of an experimental anti-aging drug and has demonstrated that older people were less susceptible to infection. This indicates a slowing of the aging immune system. This publication reports Science Alert.
The study involved 264 volunteers aged 65 years and older. They were randomly distributed into eight groups depending on the dosing regime, in the four control groups, the participants received a placebo. Subjects underwent a six-week course of two drugs-inhibitors designed to block the protein mTOR, target rapamycin in mammals. This molecule, which can bind to the immunosuppressant rapamycin, regulates the growth and survival of cells, and its deactivation leads to cell cycle arrest.
It is shown that blocking mTOR in fruit flies leads to an increase in the duration of life in insects. In addition, with the age of the mice in their cells increases the activity of the target rapamycin, which contributes to the depletion of the pool of blood stem cells, reduce the activity of the immune system and increased risk of cancer.
Two weeks after the end of the course of inhibitors, the participants received the seasonal influenza vaccine. The test results showed that the volunteers in the experimental group experienced a 20 percent increase in the number of antibodies compared with the control groups. The researchers reported no side effects. Of the patients who received inhibitors, almost twice less likely to suffer from infections within the next 12 months. This significantly reduces the risk of death from respiratory diseases that affect the elderly.
Video, photo All from Russia.